Beyond Buprenorphine: Designing Evidence-Based Opioid-Sparing Protocols in Preclinical Research

The Challenge of Pain Management in Translational Models

For decades, perioperative analgesia in laboratory animal medicine often followed a relatively simple formula: administer an opioid, monitor recovery, and provide additional doses as needed.

Today, that approach is increasingly viewed as incomplete.

As translational research becomes more sophisticated, expectations surrounding animal welfare, data quality, and clinical relevance have evolved. Sponsors and investigators are asking different questions:

• Can we reduce opioid exposure without compromising comfort?

• Can multimodal analgesia improve recovery quality?

• Do opioid-sparing protocols create more clinically relevant models?

• What evidence supports the protocols we routinely use?

The answers are not always straightforward.

While multimodal analgesia has become the accepted standard in many clinical settings, evidence supporting specific opioid-sparing strategies varies considerably across preclinical species. Some recommendations are supported by robust pharmacologic and clinical data. Others are based primarily on extrapolation, expert opinion, or institutional experience.

Understanding the distinction is critical when designing protocols intended to support both animal welfare and scientific validity.

Why Opioid-Sparing Matters

The discussion surrounding opioid reduction is often misunderstood.

The goal is not to eliminate opioids.

The goal is to minimize reliance on any single analgesic mechanism while maximizing overall pain control.

Opioids remain highly effective analgesics, but they can introduce challenges in research environments:

Physiologic Effects

Depending on species and dose, opioids may influence:

• Respiratory function

• Gastrointestinal motility

• Cardiovascular parameters

• Thermoregulation

• Sedation levels

These effects can complicate interpretation of study endpoints.

Variable Species Responses

Drugs that perform predictably in one species may produce very different effects in another.

Examples include:

• Excitatory responses in some livestock species

• Variable oral bioavailability

• Differences in receptor distribution

• Wide pharmacokinetic variability

Recovery Quality

Recovery quality often impacts both welfare and study outcomes.

Poorly controlled pain can result in:

• Delayed return to feeding

• Altered behavior

• Increased stress responses

• Secondary physiologic complications

Conversely, excessive opioid administration can prolong sedation and interfere with postoperative assessments.

Multimodal analgesia seeks to balance these competing concerns.

The Foundation: Targeting Multiple Pain Pathways

Pain is not generated through a single mechanism.

Surgical tissue injury initiates multiple physiologic processes simultaneously:

• Peripheral inflammation

• Nociceptor activation

• Central sensitization

• Sympathetic activation

• Neurochemical modulation

No single drug class addresses all of these pathways effectively.

An opioid-sparing protocol intentionally combines agents that work through different mechanisms.

A typical framework may include:

Local Anesthetics

Target:

• Peripheral nerve transmission

Examples:

• Lidocaine

• Bupivacaine

• Ropivacaine

Benefit:
Often provides the most immediate reduction in postoperative pain.

NSAIDs

Target:

• Inflammatory pathways

Examples:

• Meloxicam

• Flunixin

• Carprofen

Benefit:
Reduces inflammatory sensitization following surgery.

Opioids

Target:

• Central pain perception

Examples:

• Buprenorphine

• Morphine

• Fentanyl

Benefit:
Provides strong analgesic support during periods of highest pain intensity.

NMDA Antagonists

Target:

• Central sensitization

Examples:

• Ketamine

Benefit:
May reduce development of wind-up pain and decrease anesthetic requirements.

Alpha-2 Agonists

Target:

• Central modulation of pain pathways

Examples:

• Dexmedetomidine

• Medetomidine

Benefit:
Provides both analgesia and anesthetic-sparing effects.

The objective is not simply adding more drugs.

The objective is using smaller doses of complementary agents to achieve superior overall pain control.

Swine: The Strongest Case for Multimodal Analgesia

Among large animal models, swine currently possess one of the strongest evidence bases supporting opioid-sparing approaches.

Several factors contribute to this:

• Extensive use in translational surgical research

• Increasing cardiovascular and device studies

• Growing focus on enhanced recovery models

Modern swine protocols frequently incorporate:

• NSAIDs

• Local anesthetic infiltration

• Regional blocks

• Opioid CRIs

• Lidocaine infusions

• Ketamine infusions

One of the most important developments has been the adoption of regional anesthesia techniques.

Procedures that once relied exclusively on systemic analgesics are increasingly supplemented with:

• TAP blocks

• Intercostal blocks

• Epidural analgesia

• Wound infiltration techniques

These approaches frequently improve recovery quality while reducing total opioid requirements.

For thoracotomy and major abdominal procedures, regional anesthesia may provide the largest single improvement in postoperative comfort.

Ovine and Caprine Models: Where Evidence Begins to Thin

Sheep and goats present a different challenge.

Although these species are commonly used in orthopedic, cardiovascular, and regenerative medicine research, analgesic literature remains comparatively limited.

Many protocols rely on:

• Meloxicam

• Flunixin

• Buprenorphine

However, significant portions of current practice are based on extrapolation rather than direct validation.

This creates several concerns:

Pain Recognition

Ruminants often demonstrate subtle signs of pain.

Researchers may underestimate discomfort because:

• Behavioral changes are minimal

• Prey species mask vulnerability

• Existing scoring systems remain imperfect

Pharmacokinetic Variability

Drug metabolism may differ substantially from:

• Dogs

• Humans

• Swine

Yet recommendations are frequently borrowed from these species.

Lack of Comparative Trials

Few studies directly compare multimodal protocols within ovine or caprine models.

As a result, determining the optimal protocol remains difficult.

This area represents a significant opportunity for future translational research.

Canine Models: A Mature Analgesia Framework

Canine medicine provides perhaps the most developed veterinary evidence base outside human healthcare.

Numerous studies support:

• Regional anesthesia

• Local anesthetic blocks

• NSAID therapy

• Ketamine CRIs

• Gabapentinoids

• Opioid-sparing approaches

The discussion in canine models has shifted from proving efficacy to refining technique.

Questions now focus on:

• Which blocks provide the best outcomes?

• How long should therapy continue?

• What combinations optimize recovery?

This progression illustrates what may eventually occur in other preclinical species as evidence accumulates.

The Future of Opioid-Sparing Research

Several trends are likely to shape the next decade of perioperative analgesia.

Increased Regional Anesthesia Adoption

Ultrasound-guided techniques continue to expand.

As training and equipment become more accessible, regional anesthesia is expected to become standard in many survival models.

Objective Pain Assessment

Emerging technologies may improve our ability to measure pain through:

• Activity monitoring

• Physiologic biomarkers

• Automated behavioral analysis

More objective assessments will strengthen protocol development.

Enhanced Recovery Concepts

Human enhanced recovery after surgery (ERAS) principles are increasingly influencing preclinical protocol design.

Future models may place greater emphasis on:

• Early ambulation

• Rapid return to feeding

• Reduced anesthetic burden

• Opioid minimization

Species-Specific Validation

The greatest need remains direct validation within target species.

The future of analgesia research will depend less on extrapolation and more on generating species-specific evidence.

The Practical Reality

Developing an opioid-sparing protocol is not about following a checklist.

It requires balancing:

• Procedure severity

• Species-specific physiology

• Study objectives

• Welfare considerations

• Available evidence

The strongest protocols are rarely the most complex.

They are the protocols built upon validated science, thoughtful monitoring, and continuous refinement.

In preclinical research, pain management is more than a welfare obligation. It is a scientific variable that influences recovery, physiology, behavior, and ultimately the quality of the data generated.

As opioid-sparing strategies continue to evolve, the most successful programs will be those that recognize a simple truth:

Effective analgesia is not defined by how little opioid is used. It is defined by how well pain is controlled.

About NiKara Preclinical

NiKara Preclinical provides surgical, anesthesia, procedural, and protocol development expertise for medical device, pharmaceutical, and translational research programs. With extensive experience in swine, ovine, caprine, and canine surgical models, we help research teams develop practical, evidence-based approaches that support both scientific success and animal welfare.